Navigation Links
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
Date:6/25/2009

days. Results demonstrated a niacin dose-response relationship in both fed and fasted volunteers, with niacin being better tolerated in the fed state. Also, the most frequently reported adverse effects (AEs) were those commonly associated with niacin. These findings suggest that niacin will be well tolerated up to 60 mg per dose and will likely be well tolerated at 90 mg per dose.

Phase II Multiple-Dose Study of the Safety and Tolerability of Niacin 30 mg and 60 mg Combined With Oxycodone HCl 5 mg Versus Oxycodone HCl 5 mg Alone in Healthy Adult Volunteers

A Phase II study was conducted to evaluate the safety and tolerability of multiple daily doses of the active components of ACUROX(R) Tablets, and to determine if tolerance to the effects of niacin develops after repeat administration. Three groups of participants received different doses of niacin combined with oxycodone HCl, and the Side Effects and Symptoms Questionnaire (SESQ) and the Niacin Tolerability Rating Scale (TRS) were used to assess niacin tolerability end points. Results showed that approximately 75 percent of all volunteers in all groups rated the tolerability of study drugs as easy to tolerate or as having no effect, and that adverse effects (AEs) were consistent with the known safety profiles of oxycodone and niacin. These findings support the safety and tolerability of niacin in ACUROX(R) Tablets when taken at the recommended dose.

The Interaction Between Opioids and Alcohol: Results from a Global Literature Review

The potential risk for alcohol to interact with drugs and/or disrupt a drug formulation matrix is a prevalent safety concern. For extended-release opioids, there is an added concern that ethanol (EtOH) may disrupt the formulation mechanism leading to increased bioavailability of the opioid. Although the combination of EtOH and prescription opioids is frequently cited as having increased impairing effects, ver
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... ORLANDO, Fla. , Aug. 27, 2014 By ... Challenge, you,re likely not living on this planet. The awareness ... social consciousness and has helped to raise over $88.5 Million ... are getting involved and some companies are starting to as ... in Orlando, Florida , who actually works ...
(Date:8/27/2014)... Aug. 27, 2014 ISPE , the ... has released a preview of its Drug Shortages ... avoid drug shortages and maintain a robust and reliable ... The Plan, a first for the industry, was developed ... members and describes how industry can best prevent drug ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Heart Valve Repair ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart Valve Repair ... human heart which control the flow of blood ... heart valve diseases such as valvular stenosis, valvular ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 3ISPE Releases First Look at its Plan to Prevent Drug Shortages 4Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... 24 Schering-Plough Corporation (NYSE: SGP ... selective adenosine2a receptor antagonist, met the primary endpoint ... suffering from moderate to severe Parkinson,s disease experiencing ... The trial results were presented today at the ...
... , Dear President-Elect Obama:, , ... will start with billions of dollars,earmarked for stem cell research. ... is the voice of the Repair Stem Cell research and,treatment ... federal,funding support for our industry and the medical and scientific ...
Cached Medicine Technology:Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute 2
(Date:8/27/2014)... New York (PRWEB) August 27, 2014 ... by Transparency Market Research "Ablation Technologies Market (Applications: ... Radiofrequency, Light/Laser, Electrical, Ultrasound, Microwave, Cryotherapy) - Global ... 2014 - 2020," the global ablation technologies market ... and is estimated to reach a market worth ...
(Date:8/27/2014)... new analysis of clinical trial participation in the largest ... found participants are not representative of the larger patient ... Hospital cardiologist Dr. Jay Udell. The study authors call ... the wider population, and suggest the use of broader ... participation. , "We know that clinical trials can be ...
(Date:8/27/2014)... the onset of a cancer defense mechanism known ... Cancer Center are leveraging it in a new ... cell death rather than survival. The novel treatment ... referred to as the "Trash Man" due to ... autophagy. Results from preclinical experiments suggest this experimental ...
(Date:8/27/2014)... Disability (CLD) has received a two-year, $600,000 grant ... the Health Resources and Services Administration to support ... at improving services for children and youth with ... project, CLD worked with an Autism Advisory Council ... resulting plan addresses priorities of increased awareness of ...
(Date:8/27/2014)... (Lebanon, NH 8/27/14)Dartmouth cancer researchers developed and tested ... and environmental interactions that contribute to disease as ... , The approach fills a gap in ... from complex interactions among genetic and environmental factors. ... relevant interactions versus those that reflect chance combinations ...
Breaking Medicine News(10 mins):Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... colleagues from the Institute of Child Health will be studying ... The study will focus on the changes in their brain ... identify and understand the problems in their brain which could ... study is being funded by the Action Medical Research, UK. ...
... grow and currently affects more that 18 million ... need for alternative diabetes therapies with earlier more ... of insulin by the lung may provide an ... alternative insulin delivery systems must meet certain pharmacokinetic ...
... as the Breast Cancer Awareness Month. It is a sad ... and mortality associated with breast cancer//, very few men and ... risk factors and what is to be done in case ... Lauder, founder and president of the Breast Cancer Research Foundation, ...
... Los Angles have taken a major step forward in the ... the development of prostate cancer in animals//. ,The antibody ... and according to Dr. Robert E. Reiter, a professor of ... study's senior author it tells the cancer that it is ...
... known to express endogenous peptide antibiotics called defensins, ... active against bacteria, fungi and viruses//. ... of Nature, describes plectasin-the first defensin to be ... nigrella. Plectasin has primary, secondary and tertiary structures ...
... the deadly HIV/AIDS is accelerating in China with 126,808 ... patients, according to latest health reports//. Experts estimate that ... 80,000 AIDS patients. ,This is considerably higher than the ... over a margin of 19,818. In addition, the patients ...
Cached Medicine News:Health News:New Research To Study Brain Changes In Premature Births 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Mushroom found to be a source of a new antibiotic: Plectasin 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: